EU orphan designations
Every medicine the European Commission has designated as an orphan medicine for a rare disease, on the EMA's recommendation, with its current status.
Matching designations
2 matches| Substance | Intended use | Status | Designated |
|---|---|---|---|
| daratumumab EU/3/18/2020 100 clinical trials → |
Treatment of AL amyloidosis | Withdrawn | 25 May 2018 |
| daratumumab EU/3/13/1153 100 clinical trials → |
Treatment of plasma-cell myeloma | Expired | 17 Jul 2013 |
How this page is built
Every row is copied from the EMA's orphan designations data, reproduced with acknowledgement of the source. Each substance links to its official EMA page.
- EMA orphan designations data (JSON report) ↗ active substance, intended use, EU designation number, date of designation, status and the link to each designation page
A daily job downloads the EMA's orphan designations JSON report and lists every designation, newest first. No AI drafting and no editorial pass. See our editorial standards. The the EMA data on this page was last retrieved on 10 Oct 2026. How every register is built: methodology · fixes we have made: corrections log.